Shares of Heska Corp (NASDAQ:HSKA) have been assigned a consensus broker rating score of 1.75 (Buy) from the four brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company.
Brokerages have set a 1-year consensus price objective of $40.08 for the company and are predicting that the company will post $0.17 earnings per share for the current quarter, according to Zacks. Zacks has also given Heska Corp an industry rank of 73 out of 265 based on the ratings given to its competitors.
Several research analysts have recently issued reports on the company. B. Riley increased their target price on Heska Corp to $33.25 and gave the stock a “neutral” rating in a research report on Monday, November 9th. Zacks Investment Research lowered Heska Corp from a “buy” rating to a “hold” rating in a research report on Friday, October 30th. Finally, TheStreet raised Heska Corp from a “hold” rating to a “buy” rating in a research report on Tuesday, December 29th.
Heska Corp (NASDAQ:HSKA) opened at 38.19 on Monday. The stock has a market cap of $251.63 million and a PE ratio of 64.84. Heska Corp has a 12 month low of $15.58 and a 12 month high of $40.29. The company’s 50 day moving average price is $35.49 and its 200 day moving average price is $32.57.
Heska Corp (NASDAQ:HSKA) last announced its earnings results on Wednesday, November 11th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.08 by $0.12. The firm earned $28 million during the quarter, compared to the consensus estimate of $24.31 million. Equities analysts forecast that Heska Corp will post $0.62 EPS for the current fiscal year.
In other news, insider Michael J. Mcginley sold 958 shares of the firm’s stock in a transaction on Wednesday, November 25th. The stock was sold at an average price of $33.62, for a total value of $32,207.96. Following the transaction, the insider now directly owns 15,928 shares in the company, valued at approximately $535,499.36. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Jason A. Napolitano sold 3,700 shares of the firm’s stock in a transaction on Tuesday, December 29th. The stock was sold at an average price of $40.03, for a total value of $148,111.00. Following the completion of the transaction, the chief financial officer now owns 66,900 shares in the company, valued at $2,678,007. The disclosure for this sale can be found here.
Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The Company is focused on the canine and feline companion animal health markets. The Company operates in two segments: Core Companion Animal Health and Other Vaccines Pharmaceuticals and Products. The Core Companion Animal Health segment (NASDAQ:HSKA) includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use products and services, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. The Other Vaccines, Pharmaceuticals and Products segment (OVP) includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals including small mammals.
For more information about research offerings from Zacks Investment Research, visit Zacks.com